To include your compound in the COVID-19 Resource Center, submit it here.

Targeting opioid relapse with nanotechnology

Washington University researchers are tackling opioid relapse with nanotechnology

Backed by a grant from NIH’s National Institute on Drug Abuse, researchers from Washington University in St. Louis are attempting to prevent opioid addicts from relapsing with a therapeutic nanovaccine that will block the drugs from crossing the blood-brain barrier.

Previously developed vaccination strategies

Read the full 435 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE